| 000 | 01675 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517130240.0 | ||
| 264 | 0 | _c20170817 | |
| 008 | 201708s 0 0 eng d | ||
| 022 | _a1746-0921 | ||
| 024 | 7 |
_a10.2217/fmb-2016-0140 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aYang, Minjie | |
| 245 | 0 | 0 |
_aOptimization of linezolid treatment regimens for Gram-positive bacterial infections based on pharmacokinetic/pharmacodynamic analysis. _h[electronic resource] |
| 260 |
_bFuture microbiology _c01 2017 |
||
| 300 |
_a39-50 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnti-Bacterial Agents _xpharmacokinetics |
| 650 | 0 | 4 | _aAsian People |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Resistance, Multiple, Bacterial |
| 650 | 0 | 4 |
_aEnterococcus faecalis _xdrug effects |
| 650 | 0 | 4 |
_aGram-Positive Bacteria _xdrug effects |
| 650 | 0 | 4 |
_aGram-Positive Bacterial Infections _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLinezolid _xpharmacokinetics |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMicrobial Sensitivity Tests |
| 650 | 0 | 4 | _aMonte Carlo Method |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aStaphylococcal Infections _xdrug therapy |
| 700 | 1 | _aZhang, Jing | |
| 700 | 1 | _aChen, Yuancheng | |
| 700 | 1 | _aLiang, Xiaoyu | |
| 700 | 1 | _aGuo, Yan | |
| 700 | 1 | _aYu, Jicheng | |
| 700 | 1 | _aZhu, Demei | |
| 700 | 1 | _aZhang, Yingyuan | |
| 773 | 0 |
_tFuture microbiology _gvol. 12 _gp. 39-50 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2217/fmb-2016-0140 _zAvailable from publisher's website |
| 999 |
_c26670927 _d26670927 |
||